Eli Lilly, the makers of tirzepatide—which they sell as Mounjaro for diabetes and Zepbound for weight loss— announced recently that in its longest study yet on tirzepatide, the drug reduced the risk of people with prediabetes moving on to develop diabetes by 94% compared to those taking a placebo.

Weight loss drugs are all the rage right now. From the more popular options like Mounjaro or Ozempic – which is technically a diabetes medication that also helps with weight management – to emerging medications like WeGovy and Zepbound,

Ozempic and other weight-loss injections have recently been revolutionising the treatment of obesity. But this transformation may be nothing compared to the impact of the next generation of weight-loss drugs, which will be available in tablet form, with early results suggesting it will be even more potent.

The success of weight-loss injections has prompted pharmaceutical companies to produce a next-generation anti-obesity pill